In addition to these briefly outlined challenges for pathologists in distinguishing between HER2-low and HER2-zero, another fundamental problem is discordance between the primary tumor and corresponding metastases, since whenever possible, a recent metastatic biopsy is encouraged to guide therapy in advanced breast cancer. Here, ERBB2 is linked to breast cancer.